Abstract
A soluble form of the complement receptor CD21 (sCD21) is shed from the lymphocyte surface. The sCD21 is able to bind all known ligands such as CD23, sCD23, Epstein-Barr virus and C3d in immune complexes. Here, we show the serum levels of sCD21 in sera the of antiphospholipid syndrome (APS) patients. Antiphospholipid syndrome is an autoimmune disorder in which autoantibodies cause heart attack, stroke and miscarriage. Antiphospholipid syndrome may appear as primary or in association with systemic lupus erythromatosus (SLE) and other autoimmune diseases. Here, we ask whether APS patients have different sCD21 titers compared to healthy persons and whether sCD21 levels correlate with the presence of anti-β2-GPI autoantibodies. We show that autoimmune APS patients have significantly reduced amounts of sCD21 in their sera, irrespective of the presence of anti-β2-GPI autoantibodies. In our APS patients cohort additional SLE, vasculities, DVT (deep vein thrombosis), fetal loss or thrombosis did not correlate to the reduced level of sCD21.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Timens W, Boes A, Rozeboom-Uiterwijk T, Poppema S (1989) Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J Immunol 143(10):3200–3206
Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY (1992) CD21 is a ligand for CD23 and regulates IgE production. Nature 358(6386):505–507
Masilamani M, Kassahn D, Mikkat S, Glocker MO, Illges H (2003) B cell activation leads to shedding of complement receptor type II (CR2/CD21). Eur J Immunol 33(9):2391–2397
Masilamani M, von Seydlitz E, Bastmeyer M, Illges H (2002) T cell activation induced by cross-linking CD3 and CD28 leads to silencing of Epstein-Barr virus/C3d receptor (CR2/CD21) gene and protein expression. Immunobiology 206(5):528–536
Ling N, Hansel T, Richardson P, Brown B (1991) Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia. Clin Exp Immunol 84(1):16–22
Myones BL, Ross GD (1987) Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site. Complement 4(2):87–98
Weis JJ, Tedder TF, Fearon DT (1984) Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes Proc Natl Acad Sci USA 81(3):881–885
Huemer HP, Larcher C, Prodinger WM, Petzer AL, Mitterer M, Falser N (1993) Determination of soluble CD21 as a parameter of B cell activation. Clin Exp Immunol 93(2):195–199
Reynes M, Aubert JP, Cohen JH, Audouin J, Tricottet V, Diebold J, Kazatchkine MD (1985) Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol 135(4):2687–2694
Tsoukas CD, Lambris JD (1988) Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies. Eur J Immunol 18(8):1299–1302
Hebell T, Ahearn JM, Fearon DT (1991) Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 254(5028):102–105
Qin D, Wu J, Carroll MC, Burton GF, Szakal AK, Tew JG (1998) Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses. J Immunol 161(9):4549–4554
Fischer E, Delibrias C, Kazatchkine MD (1991) Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol 146(3):865–869
Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT (1984) Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 81(14):4510–4514
Lowe J, Brown B, Hardie D, Richardson P, Ling N (1989) Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia. Immunol Lett 20(2):103–109
Delibrias CC, Fischer E, Bismuth G, Kazatchkine MD (1992) Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL. J Immunol 149(3):768–774
Moore MD, DiScipio RG, Cooper NR, Nemerow GR (1989) Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2). J Biol Chem 264(34):20576–20582
Masilamani M, Nowack R, Witte T, Schlesier M, Warnatz K, Glocker MO, Peter HH, Illges H (2004) Reduction of soluble complement receptor 2/CD21 in systemic lupus erythomatosus and Sjogren’s syndrome but not juvenile arthritis. Scand J Immunol 60(6):625–630
Fremeaux-Bacchi V, Fischer E, Lecoanet-Henchoz S, Mani JC, Bonnefoy JY, Kazatchkine MD (1998) Soluble CD21 (sCD21) forms biologically active complexes with CD23: sCD21 is present in normal plasma as a complex with trimeric CD23 and inhibits soluble CD23-induced IgE synthesis by B cells. Int Immunol 10(10):1459–1466
Ulgiati D, Pham C, Holers VM (2002) Functional analysis of the human complement receptor 2 (CR2/CD21) promoter: characterization of basal transcriptional mechanisms. J Immunol
168(12):6279–6285
Hannan J, Young K, Szakonyi G, Overduin MJ, Perkins SJ, Chen X, Holers VM (2002) Structure of complement receptor (CR) 2 and CR2-C3d complexes. Biochem Soc Trans 30(Pt 6):983–989
Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335(8705): 1544–1547
Masilamani M, von Kempis J, Illges H (2004) Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis. Rheumatology 43(2):186–190
Sammaritano LR, Gharavi AE (1992) Antiphospholipid antibody syndrome. Clin Lab Med 12(1):41–59
Shoenfeld Y (2003) Systemic antiphospholipid syndrome. Lupus 12(7):497–498
Blank M, Tincani A, Shoenfeld Y (1994) Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies. J Rheumatol 21(1):100–104
George J, Blank M, Levy Y, Meroni P, Damianovich M, Tincani A, Shoenfeld Y (1998) Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 97(9):900–906
Blank M, Cohen J, Toder V, Shoenfeld Y (1991) Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 88(8):3069–3073
Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E (1999) Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 96(9):5164–5168
Blank M, George J, Barak V, Tincani A, Koike T, Shoenfeld Y (1998) Oral tolerance to low dose beta 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome. J Immunol 161(10):5303–5312
Meroni P, Ronda N, Raschi E, Borghi MO (2005) Humoral autoimmunity against endothelium: theory or reality? Trends Immunol 26(5):275–281
Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, Tobar A, Shoenfeld Y (2002) Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 109(6):797–804
Masilamani M, Apell HJ, Illges H (2002) Purification and characterization of soluble CD21 from human plasma by affinity chromatography and density gradient centrifugation. J Immunol Methods 270(1):11–18
Lyubchenko T, dal Porto J, Cambier JC, Holers VM (2005) Coligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway. J Immunol 174(6):3264–3272
Szakonyi G, Guthridge JM, Li D, Young K, Holers VM, Chen XS (2001) Structure of complement receptor 2 in complex with its C3d ligand. Science 292(5522):1725–1728
Carel JC, Myones BL, Frazier B, Holers VM (1990) Structural requirements for C3d, g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J Biol Chem265(21):12293–12299
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Physica-Verlag Heidelberg
About this chapter
Cite this chapter
Singh, A., Blank, M., Shoenfeld, Y., Illges, H. (2009). Antiphospholipid Syndrome Patients Display Reduced Titers of Soluble CD21 in Their Sera Irrespective of Circulating Anti-β2-Glycoprotein-I Autoantibodies. In: Zacharias, C., et al. Forschungsspitzen und Spitzenforschung. Physica-Verlag HD. https://doi.org/10.1007/978-3-7908-2127-7_30
Download citation
DOI: https://doi.org/10.1007/978-3-7908-2127-7_30
Publisher Name: Physica-Verlag HD
Print ISBN: 978-3-7908-2126-0
Online ISBN: 978-3-7908-2127-7
eBook Packages: Humanities, Social Science (German Language)